Pharmaceutical Solutions Company Singapore | Rxilient

Rxilient is pleased to announce that it has entered a partnership with Polichem, a subsidiary of Almirall S.A., for two dermatology products:

We're pleased to share that 露美瑞乳膏 Lumirix® (Ruxolitinib) Cream 15mg/g has received official approval in Taiwan.

​Rxilient Medical and Delova Biotech have entered into an exclusive licensing for the commercialization of QP001, a novel long-acting meloxicam injection for post-operative pain management. QP001 has already been approved and marketed in the United States under the brand name Qamzova, and in China as 普坦宁® (Putanning).

We are pleased to release the news that on 30 December 2022, that we have through Rxilient Medical Pte. Ltd. acquired a potential blockbuster innovative product in dermatology filed from CMS Aesthetics by entering into a sublicense and collaboration agreement obtaining the license for the development, production, registration and commercialization of Ruxolitinib cream in Taiwan and eleven countries in Southeast Asia (“Territory”), commencing on its effective date.